Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Lymphocytic Leukemia

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL

Leukemia volume 25, pages 1452–1458 (2011)Cite this article

Subjects

Abstract

Chronic lymphocytic leukemia (CLL) cells require complex microenvironmental and immunologic interactions to survive and proliferate. Such interactions might be best recreated in animal models; however, this needs extensive verification. We therefore investigated the composition of the T-cell compartment in the Eμ-TCL1 transgenic mouse, currently the most widely used murine model for CLL. Immunophenotyping and transplant approaches were used to define T-cell subsets at various stages of CLL. Analogous to human CLL, we observed a skewing of T-cell subsets from naive to antigen-experienced memory T cells that was more pronounced in lymph nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible without immunosuppression in a pure C57BL/6 background and resulted in the prominent skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant number of clonal T-cell populations arising. This suggests that antigen-dependent differentiation toward the T memory pool is initiated by murine CLL cells. In summary, we validate the TCL1 transgenic mouse model for analysis of T-cell phenotypes and suggest a CLL-dependent antigen-driven skewing of T cells in these mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Caligaris-Cappio F, Ghia P . Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497–4503.

    Article  CAS  PubMed  Google Scholar 

  2. Ghia P, Chiorazzi N, Stamatopoulos K . Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008; 264: 549–562.

    Article  CAS  PubMed  Google Scholar 

  3. Chiorazzi N, Ferrarini M . Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematol Am Soc Hematol Educ Program 2006; 273–278: 512.

    Google Scholar 

  4. Chiorazzi N . Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399–413.

    Article  CAS  PubMed  Google Scholar 

  5. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755–764.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008; 111: 5173–5181.

    Article  CAS  PubMed  Google Scholar 

  7. Mellstedt H, Choudhury A . T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006; 55: 210–220.

    Article  CAS  PubMed  Google Scholar 

  8. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998; 91: 4273–4281.

    CAS  PubMed  Google Scholar 

  9. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427–2437.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R . Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 2009; 32: 302–309.

    Article  CAS  PubMed  Google Scholar 

  11. Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007; 67: 8653–8661.

    Article  PubMed  Google Scholar 

  12. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955–6960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Noguchi M, Ropars V, Roumestand C, Suizu F . Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J 2007; 21: 2273–2284.

    Article  CAS  PubMed  Google Scholar 

  14. Teitell MA . The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer 2005; 5: 640–648.

    Article  CAS  PubMed  Google Scholar 

  15. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009; 114: 4675–4686.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Schlette E, Tam CS, Herling M, Buenso-Ramos C, Wierda W, Ferrajoli A et al. High T-cell lymphoma breakpoint 1 (TCL1) levels are associated with lack of response and inferior outcome following fludarabine, cyclophosphamide, rituximab (FCR) frontline therapy in patients with chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). Ref Type: Abstract 2010; 112: 2086.

    Google Scholar 

  17. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713–11718.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009; 8: 3663–3667.

    Article  CAS  PubMed  Google Scholar 

  19. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 13433–13438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469–4476.

    Article  CAS  PubMed  Google Scholar 

  21. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009; 113: 2791–2794.

    Article  CAS  PubMed  Google Scholar 

  22. Sanchez-Aguilera A, Rattmann I, Drew DZ, Muller LU, Summey V, Lucas DM et al. Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia 2010; 24: 97–104.

    Article  CAS  PubMed  Google Scholar 

  23. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250–6255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P . The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993; 90: 4319–4323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Garcia C, Rosen A, Kimby E, Aguilar-Santelises M, Jondal M, Bjorkhilm M et al. Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS). Leuk Res 1989; 13: 31–37.

    Article  CAS  PubMed  Google Scholar 

  26. Kimby E, Mellstedt H, Nilsson B, Bjorkholm M, Holm G . T lymphocyte subpopulations in chronic lymphocytic leukemia of B cell type in relation to immunoglobulin isotype(s) on the leukemic clone and to clinical features. Eur J Haematol 1987; 38: 261–267.

    Article  CAS  PubMed  Google Scholar 

  27. Bingaman AW, Patke DS, Mane VR, Ahmadzadeh M, Ndejembi M, Bartlett ST et al. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol 2005; 35: 3173–3186.

    Article  CAS  PubMed  Google Scholar 

  28. Dutton RW, Bradley LM, Swain SL . T cell memory. Annu Rev Immunol 1998; 16: 201–223.

    Article  CAS  PubMed  Google Scholar 

  29. Farber DL . T cell memory: heterogeneity and mechanisms. Clin Immunol 2000; 95: 173–181.

    Article  CAS  PubMed  Google Scholar 

  30. Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H . Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999; 94: 1063–1069.

    CAS  PubMed  Google Scholar 

  31. Rezvany MR, Jeddi-Tehrani M, Wigzell H, Osterborg A, Mellstedt H . Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 2003; 101: 1063–1070.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Austrian FWF Grants P19481 and L488 to AE, Austrian National Bank Grant 10990 to AE and by the state of Salzburg and the SFB 021 to RG. TCR CDR3 spectratyping was performed at the Children's Hospital of the Federal Hospital of Salzburg.

Author contributions AE, JPH, IT and RG designed the research; JPH, ChH, UD, TK, ClH, DT and DA performed the experimental work; AE and JPH performed the analysis; AE and JPH wrote the paper. All authors were involved in critical discussion of the manuscript.

Author information

Author notes

  1. I Tinhofer

    Present address: 2Current address: Translational Radiobiology and Radiooncology Research Laboratory, Clinical Department for Radiotherapy (CCM/CVK), Charité University Hospital Berlin, Berlin, Germany.,

Authors and Affiliations

  1. 3rd Medical Department for Hematology, Laboratory for Immunological and Molecular Cancer Research, Medical Oncology, Hemostasiology, Infectious Diseases, and Rheumatology, Federal Hospital of Salzburg and Paracelsus Medical Private University, Salzburg, Austria

    J Piñón Hofbauer, C Heyder, U Denk, T Kocher, C Holler, D Trapin, D Asslaber, I Tinhofer, R Greil & A Egle

Authors
  1. J Piñón Hofbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Heyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Denk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Kocher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Holler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Trapin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Asslaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Tinhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Greil
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Egle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Egle.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofbauer, J., Heyder, C., Denk, U. et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 25, 1452–1458 (2011). https://doi.org/10.1038/leu.2011.111

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.111

Keywords

This article is cited by

Search

Advanced search

Quick links